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Abstract: To investigate the effects of oral bacteriotherapy on intestinal phenylalanine and tyrosine
metabolism, in this longitudinal, double-arm trial, 15 virally suppressed HIV+ individuals underwent
blood and fecal sample collection at baseline and after 6 months of oral bacteriotherapy. A baseline
fecal sample was collected from 15 healthy individuals and served as control group for the baseline
levels of fecal phenylalanine and tyrosine. CD4 and CD8 immune activation (CD38+) was evaluated by
flow cytometry. Amino acid evaluation on fecal samples was conducted by Proton Nuclear Magnetic
Resonance. Results showed that HIV+ participants displayed higher baseline phenylalanine/tyrosine
ratio values than healthy volunteers. A significand reduction in phenylalanine/tyrosine ratio and
peripheral CD4+ CD38+ activation was observed at the end of oral bacteriotherapy. In conclusion,
probiotics beneficially affect the immune activation of HIV+ individuals. Therefore, the restoration of
intestinal amino acid metabolism could represent the mechanisms through which probiotics exert
these desirable effects.
Keywords: HIV; probiotics; phenylalanine; tyrosine; metabolism; inflammation; neurocognitive
impairment
1. Introduction
Despite the widespread use of antiretroviral drugs and the subsequent achievement of viral
suppression in most infected individuals, the HIV population is still facing a high prevalence of
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non-AIDS defining conditions related to the high levels of immune activation [1]. Growing evidences
support the role of gut resident bacteria in the pathogenesis of the persistence of immune activation [2,3]
and in the onset of neurologic disorders like major depression and autism, as well as in the regulation
of mood and behaviour (the microbiota–gut–brain axis) [4–6]. Several studies performed in mice
showed that a depressive phenotype can be transferred with fecal transplantation [7], confirming the
profound importance of gut microbes in the regulation of brain activity. The imbalance of gut bacterial
species, usually referred as dysbiosis, plays an important role in the onset of such alterations through
the interference with amino acid absorption and metabolism and through the modification of the
synthesis of microbiota-derived bioactive products [8]. Gut dysbiosis represents one of the hallmarks
of HIV infection, even in patients on antiretroviral treatment and with undetectable levels of HIV
viraemia [2]. The metabolism of aromatic amino acids such as tryptophan (precursor of serotonine),
phenylalanine (Phe) and tyrosine (Tyr, precursors of catecholamines) is disrupted in HIV-1 infected
individuals with subsequent implications in the pathogenesis of neurocognitive alterations in this
population [9]; moreover, the modification of tryptophan catabolism observed in this population
have been linked to cognitive impairment and depression, as a consequence of a reduced synthesis of
serotonin and an accumulation of neurotoxic metabolites [10–13]. Phenylalanine and tyrosine represent
precursors in the pathway of the synthesis of catecholamines, thus alterations in their metabolism and
a diminished conversion of Phe to Tyr by the enzyme phenylalanine-hydroxylase (PAH), could lead
to a reduced cognitive performance [8,14]; by the way the metabolism of these two amino acids in
the setting of HIV infection has not been extensively investigated as that of tryptophan. Alterations
of phenylalanine/tyrosine ratio have been observed in different inflammatory conditions such as
sepsis, cancer and in the elderly, as well as in HIV infection [14]. In HIV positive individuals, an
increased phenylalanine/tyrosine ratio has been recognized as a marker of immune activation and
as a surrogate indicator of a reduced activity of tetrahydrobiopterin, a fundamental co-factor in the
pathway of the synthesis of dopamine and the other catecholamines [15]. However, more data are
necessary before firm conclusions can be drawn. Supplementation of antiretroviral (ARV) therapy
with oral probiotics showed the ability to modulate gut microbial species, restoring gut mucosal
immunity and thus potentially decreasing microbial translocation and immune activation [16–18].
Furthermore, probiotics showed the ability to improve neurocognitive function and reduce immune
activation in this population [19,20]. However, it remains unclear whether probiotics supplementation
can affect the metabolism of aromatic amino acids, as Phe and Tyr, in HIV-1 infected patients. Hence,
given the impact of gut microbiota activity on the metabolism of aromatic amino acids involved in the
regulation of cognitive function [7–13], and considering that neurocognitive decline can be improved
with probiotics intake in HIV+ patients [19,20], we hypothesized that gut microbes composition might
modulate neuroinflammation and neurocognitive functions through the effect on the balance of Phe
and Tyr during HIV-1 infection. With the present study we aimed to evaluate, for the first time to
our knowledge, the effect of supplementation with oral probiotics on phenylalanine and tyrosine




Overall, 15 subjects were enrolled in the study (3 not meeting inclusion criteria, 6 declined to
participate). All subjects in the study were adult Caucasian males (Table 1).
The median age of HIV+ participants was 42 (range: 24–56) years old. Median time from HIV
diagnosis was 12 (range: 3–28) years, while median duration of ARV therapy was 8 (range: 1–17) years;
all subjects were on a stable ARV regimen since at least 6 months prior to enrollment. The median T
CD4 nadir count was 247 (range: 25–560) cell/µL, while the T CD4 count at enrollment was 736 (range:
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493–1315) cell/µL. All HIV+ patients had no co-infections at enrollment. Individuals in the healthy
control (HC) group were age and gender matched to the HIV+ participants.
Table 1. Characteristics of HIV+ subjects enrolled in the study.
Characteristics HIV+ Patients a Healthy Controls
N of subjects 15 15
Males 15 15
Age 42 (24–56) 41 (25–57)
Years from diagnosis 12.4 (3–28) NA
Years on ARV treatment 8 (1–17) NA
T CD4 nadir 247 (25–560) cell/µL NA








a Data were expressed as median values; range is reported between brackets). Abbreviations: ARV: antiretroviral;
CD4: cluster of differentiation 4, PI: Protease Inhibitor; NRTI: Nucleoside Reverse transcriptase inhibitor; NNRTI:
Non-nucleoside reverse-transcriptase inhibitor; NtRTI: Nucleotide reverse transcriptase inhibitor; INSTI: Integrase
Strand Transfer Inhibitor.
2.2. Effects of Probiotics on Peripheral Immune Activation
HIV+ participants underwent blood sampling at T0 and T6 to evaluate peripheral immune
activation defined as the proportion of CD4+ and CD8+ T cells expressing CD38. At T6 we observed a
significant decrease of CD4+ CD38+ T cells (median values: T0: 7.65% vs. T6: 4.11%, p = 0.012) and a
trend toward the reduction of CD8+ CD38+ T cells (median values: T0: 3.70% vs. T6: 1.46%, p = 0.075).
2.3. Effects of Probiotics on Phenylalanine and Tyrosine Metabolism
HIV+ participants provided fecal samples at T0 and T6 (after 6 months of supplementation with
oral probiotics).
The comparison of fecal phenylalanine and tyrosine concentration between HC and HIV+ patients
at T0 and T6 are shown in Figure 1. Instead, the comparison of phenylalanine/tyrosine ratio (Phe/Tyr)
between HC and HIV+ patients at T0 and T6 after supplementation with oral probiotics are shown in
Figure 2.
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Figure 1. Phenylalanine and tyrosine fecal concentrations in HC and HIV+ patients before T0 and 
after T6 oral probiotics supplementations. (A) Phenylalanine fecal concentration in HC and HIV+ 
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Figure 1. Phenylalanine and tyrosine fecal concentrations in HC and HIV+ patients before T0 and
after T6 oral probiotics supplementations. (A) Phenylalanine fecal concentration in HC and HIV+
subjects measured before T0 and aft r T6 suppl men ation with oral probiotics. (B) Tyr sine fecal
concentration in HC and HIV+ subjec s before T0 and after T6 supplementa ion with oral probiotics.
The line indicates median population value. Data were analyzed using the Mann–Whitney t st for
unpaired samples and Wilcoxon test for paired samples.
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Figure 3. (A) Mean relative differences of HIV negative individuals from normal level of 
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values of tyrosine. The tyrosine has been measured in the pre (T0) and post-treatment (T6). Average 
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Figure 2. Phenylalanine/tyrosine ratio (Phe/Tyr) in HC and HIV+ subjects measured before T0 and
after T6 supplementation with oral probiotics. The line indicates median population value. Data were
analyzed using the Mann–Whitney test for unpaired samples and Wilcoxon test for paired samples.
At baseline HIV+ patients showed a higher Phe/Tyr ratio than healthy controls [HIV+ T0: 13.6
(6–67.1) µmol/g vs. HC: 12.2 (4.67–15.8) µmol/g; p = 0.011]; Figure 2) while Phe [HIV+ T0: 2.1 × 10−3
(0.4 × 10−3–2.2 × 10−3) µmol/g vs. HC: 2.8 × 10−3 (2.1 × 10−3–3.9 × 10−3) µmol/g] and Tyr levels [HIV+
T0: 2.0 × 10−3 (4.23 × 10−5–3.2 × 10−4) µmol/g vs. HC: 2.7 × 10−4 (1.8 × 10−4–4.7 × 10−4) µmol/g] were
not different between the two groups analyzed (p > 0.05, Figure 1). After probiotics supplementation,
both Phe levels [HIV+ T6: 1.85 × 10−3 (0.8 × 10–4.9 × 10−3) µmol/g] and Phe/Tyr ratio [HIV+ T6: 4.23
(0.76–44.9) µmol/g] decreased in HIV−1 infected patients (Phe: T0 vs. T6 p = 0.004; Figure 1; Phe/Tyr
ratio: p = 0.002; Figure 2). By contrast, Tyr levels were higher at T6 compared to those at T0 (HIV+ T6:
3.4 × 10−4 (1.1 × 10−4–1.5 × 10−3 µmol/g, p = 0.017; Figure 1).
As an internal control, cut-off values based on uninfected populations were calculated to
define the normal level for phenylalanine 0.8 (0.1–3.9) µmol/g, tyrosine 0.4 (0.1–0.7) µmol/g and
phenylalanine/tyrosine ratio 7.2 (2.6–18.5). When we compared amino acids concentration at T0 and
T6 between HIV+ subjects and normal level, we observed that HIV+ individuals showed significantly
relative differences of concentrations [Phe: Pre, 60% (57–63%) vs. Post, −18% (−17.1–−18.9%); Tyr:
Pre, −45% (−42.75–−47.25%) vs. Post, 10% (9.5–10.5%); Phe/Tyr: Pre, 30% (28.5–31.5%) vs. Post,
15% (14.25–15.75%)] (Figures 3 and 4).
A multivariate analysis confirmed the beneficial effect of oral probiotics on phenylalanine reduction,
tyrosine increase and Phe/Tyr decrease (p < 0.001, F 31.391).
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Figure 3. (A) Mean relative differences of HIV negative individuals from normal level of phenylalanine.
The phenylalanine concentration has been measured in the pre (T0) and post (T6) treatment of
probiotics. (B) R lativ diff rences in percentage of HIV n gative subjects fro normal values of
tyrosine. The tyrosin has bee measured in the pre (T0) and post-treatment (T6). Average (grey:
untreated; white: treated).
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2.4. Effects of Probiotics on Neuroinflammation and Cognitive Function
Cerebrospinal fluid (CSF) neopterin level and neurocognitive performance in HIV+ patients were
evaluated at baseline and after six months of probiotic intake. Baseline CSF neopterin concentration
was found to be above the normal threshold (9–20 nmol/L) [21] in all investigated HIV-1 positive
subjects (mean value: 42.26 ± 6.78 nmol/L). Neopterin concentration in CSF was significantly reduced
after supplementation with oral probiotics (mean value: 29.29 ± 13.8 nmol/L; T0 vs. T6, p = 0.002).
Supplement tion with oral probiotics exerted a positive effect on neurocognitive function of HIV-1
infect d particip nts (Table 2). At baseline, all HIV p sitive subjects showed impaired results in at
least one neurocognitive test and mos of the showed impairme t in two different cogni ve domains.
At T6, all participants showed a normal neurocognitive performance with sig ificant improvements
observed in s veral of the performed ests (Table 2).
Table 2. Neurocognitive tests performance of HIV+ participants.
Neurocognitive Tests T0 a T6 a Statistical Significance
Rey–Osterrieth Complex Figure (immediate recall) 16.4 22.1 0.002
Rey–Osterrieth Complex Figure (delayed recall) 16.2 23.3 0.002
Rey Auditory Verbal Learning Test (immediate recall) 43.0 52.7 0.460
Rey Auditory Verbal Learning Test (delayed recall) 8.6 11.9 0.054
Rey Auditory Ver al Learning Test (recognition) 94.5 98.9 0.099
Verbal Fluency 14.8 15.6 0.364
Phonological Verbal Fluency 30.1 42.6 0.035
Semantic Verbal Fluency 44.5 47.7 0.034
Visual Search Test (attentive matrices) 50.2 47.9 0.079
Test of Weights and M sures Estimation (time) 17.5 23.0 .400
Test of Weights and Measu es Estimation (weight) 17.5 22.0 0.034
Test of Weights and Measures Estimation (total) 37.1 44.7 0.731
Raven’s Standard Progressive Matrices 27.0 30.6 0.202
Verbal Span (forward) 4.6 5.3 0.285
Verbal Span (backward) 4.4 4.6 1.000
Corsi Block Tapping Test (forward) 4.6 5.2 0.117
Corsi Block Tapping Test (backward) 3.7 4.12 0.351
Aachener Aphasia Test 9.0 9.0 1.000
Trail Making Test A 54.3 46.0 0.120
Trail Making Test B 127.1 108.9 0.413
a Data were expressed as mean values. Significant differences (p < 0.05) were highlighted in bold.
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2.5. Measure of Adherence to Probiotics Intake and Safety of the Intervention
Adherence to probiotic prescription was evaluated and confirmed with the observation of
an increased fecal concentration of Bifidobacteria spp. after 2 months (T2) [T0: 7.70 (7.52–7.91)
Bifidobacteria/g of feces (log10) vs. T2 8.06 (7.71–8.14) Bifidobacteria/g of feces (log10); p = 0.021) and 6
months of probiotics intake [T6: 8.0 (7.55–8.35) Bifidobacteria/g of feces (log10); T0 vs. T6, p = 0.028) in
each participant. No side effects were reported during the period of probiotics intake.
3. Discussion
An increased risk of developing neurocognitive disorder is a common outcome related to HIV-1
infection [4–7] and a growing body of evidence supports the pivotal role played by gut microbiota
in the modulation of cognitive function [22]. This influence is exerted through several mechanisms
that include the synthesis of short-chain fatty acids and other bioactive metabolites by intestinal
bacteria as well as the modulation of peripheral and central activity of neurotransmitters [4–7].
Phe and Tyr, that represent precursors for the synthesis of dopamine, also seem to play a critical
role in the balance of neurocognitive function, as highlighted by peculiar conditions, in which PAH
function appears to be impaired [23]. Accordingly, with the present study, we aimed to evaluate
the fecal concentrations of phenylalanine and tyrosine and the Phe/Tyr in a population of HIV-1
infected individuals with subclinical cognitive impairment; since HIV-1 infection holds a significant
impact on gut microbial species metabolism [24], we therefore evaluated the impact of long term oral
probiotics intake on phenylalanine and tyrosine metabolism and the effect of probiotics on patients’
cognitive performance. To do so, we evaluated the fecal concentrations of the two amino acids in a
group of HIV-1 infected participants before and after probiotic supplementation; fecal amino acid
concentrations were also evaluated in a control group of age and gender matched HIV negative
individuals. Subclinical neurocognitive impairment was investigated in HIV-1 infected participants
with a complex neurocognitive test battery developed and administered by a neuropsychologist and
with the evaluation of CSF neopterin concentration.
At baseline, we observed higher fecal Phe/Tyr and similar fecal Phe and Tyr concentrations in
HIV positive participants than in healthy controls and this was not surprising, given the fact that
in the setting of HIV infection Phe/Tyr is correlated to markers of systemic immune activation [14].
In this context, amino acid status of HIV-1 infected patients significantly differs from that of healthy
controls and this could be explained by differences in intestinal absorption, amino acid utilization
and requirement and inflammatory biomarkers [25]. Moreover, in HIV positive subjects as well as
in negative individuals, phenylalanine and tyrosine represent precursors involved in the synthesis
of catecholamines, such as dopamine; Phe/Tyr is usually considered a marker of the activity of
tetrahydrobiopterin, the enzyme that catalyzes the first step of the pathway of catecholamines synthesis
(the transformation of phenylalanine into tyrosine), therefore an elevated Phe/Tyr has been associated
with a reduced level of dopamine [14] and subsequently with imbalanced cognitive abilities. Compared
to total amino acids, the impairment in the enzymatic conversion of Phe is strongly related to clinical
symptoms like depressive mood [26–28] and the worsening of life quality [29–31], especially in HIV-1
infected patients, due to the association between the Phe metabolism and HIV-1 pathology [18].
Accordingly, the increased Phe/Tyr observed in HIV+ participants at baseline is consistent with the
subclinical cognitive alteration observed in the same group of patients and with the neuroinflammation
status at CNS level, assessed by CSF neopterin measurement, which results deeply altered compared
to the normal range observed in healthy adult individuals [21]. In this regard, Zangerle et al. observed
a strong association between Phe/Tyr ratio and Phe and Tyr concentrations and neopterin in urine
and plasma of HIV-1 infected patients that could be explained by the ability of pro-inflammatory
stimuli like Interferon-γ (IFN-γ) to induce the release of neopterin, by dendritic cells and human
monocyte derived macrophages [14,32]. Moreover, increased neopterin levels might in turn promote
the production of large quantities of reactive oxygen species (ROS) [33]. During this condition of high
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oxidative stress, tetrahydrobiopterin (BH4), the natural cofactor of PAH, is destroyed, so that proper
function of PAH could be altered [34].
Notably, probiotics are known to promote the restoration of gut mucosal integrity of HIV-1
infected individuals, favoring the reduction of the translocation of microbial derived products in
the blood and thus exerting anti-inflammatory effects at the systemic level and in the CNS [16,17],
with positive outcomes in terms of cognitive function. In our study population, oral supplementation
with probiotics exerted a favorable action promoting a decrease in fecal phenylalanine and an
increase in fecal tyrosine concentrations with a subsequent improvement of fecal Phe/Tyr. Of note,
after probiotics supplementation HIV positive subjects showed a lower Phe/Tyr than healthy controls.
Thus, as combined antiretroviral therapy (cART) leads to a decrease on HIV-1 replication, the related
reduction of neuroinflammation observed in our HIV-1 infected patients could be coherent not only with
neopterin concentration but also with ROS decrease and, consequently, with the reduction in oxidative
stress. The latter condition could improve the activity of BH4 and boost PAH function [14,15]. One of the
consequences of the above proposed mechanisms could be the increase of Tyr concentration, which is a
primary intermediate of catecholamines neurotransmitters synthesis [14,15]. However, this conclusion
could be limited by the fact that, in this study, any measurement of PAH or neurotransmitters levels was
not performed. However, these modifications of the intestinal amino acid metabolism in HIV+ patients
can partly be attributed to the modulation of the metabolic activity of the gut resident bacteria and partly
to the reduction of the systemic and central immune activation demonstrated by the observation of a
lower proportion of circulating activated CD4 and CD8 T cells and of a lower neopterin concentration
in CSF. Interestingly, metabolic pathways of intestinal microbiota significantly have been shown to be
correlate with marker of T cell activation as CD38, bacterial translocation (BPI, sCD14), LPS biosynthesis
and inflammation [35]. Anyway, independently from which was the predominant mechanism, from the
phenotype point of view at the end of probiotics supplementation HIV-1 infected subjects showed an
amelioration of neurocognitive performance. Moreover, given the strong connection between the CNS
function and the intestinal microenvironment, the analysis performed in this study aimed to obtain
more insights into the gut–brain axis and to understand if and how probiotics could impact on this
complex bidirectional crosstalk and act directly on T cell immune activation [36,37].
4. Materials and Methods
4.1. Study Design, Study Population and Ethical Statement
This longitudinal, double-arm study included HIV+ subjects on stable and effective cART enrolled
at the HIV Outpatient Clinic of the Department of Infectious Diseases of Sapienza, University of Rome
and healthy volunteers.
Out of 24 HIV+ patients screened, 15 HIV+ subjects responded to the eligibility characteristics and
were enrolled in the study (3 not meeting inclusion criteria, 6 declined to participate). All subjects in the
study were adult Caucasian males. As an internal control, phenylalanine and tyrosine concentrations
were measured in 15 age and gender matched healthy uninfected subjects, following the same
nutritional habits as the HIV+ group and with no neurological and behavioral alterations
The study was approved by the internal committee of the Public Health and Infectious Diseases
Department and by the Ethics Committee of Sapienza, University of Rome (Ref. 2970). Prior to the
enrolment, all HIV+ and healthy participants gave their written informed consent to be included in
the study.
4.2. Eligibility Criteria
Inclusion criteria for the enrollment in the study were: age >18 years old, a stable (at least 6 months
prior to inclusion) and effective (plasma HIV RNA <37 copies/mL) HAART regimen. Exclusion criteria
were: education below primary school, Mini Mental State Examination <26, any impairment in daily
living activities as defined in the Instrumental Activities of Daily Living scale, previous history or actual
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diagnosis of any neurologic or psychiatric condition, positive PCR on CSF for any of the following
pathogens: Citomegalovirus (CMV), Epstein-Barr virus (EBV), Herpes simplex virus 1 (HSV1), Herpes
simplex virus 2 (HSV2), Varicella-zoster virus (VZV), Human herpes virus 8 (HHV8), BK virus (BKV),
John Cunningham virus (JCV).
4.3. Study Timeline and Investigational Compound
All HIV+ participants underwent blood, fecal and CSF sampling and neurocognitive evaluation
at baseline (T0) and after six months (T6) of supplementation with a commercially available
multistrain probiotic formulation (trade name: Vivomixx® in EU and Visbiome® in USA. Composition:
Streptococcus thermophilus DSM24731, Bifidobacterium breve DSM24732, Bifidobacterium longum DSM24736,
Bifidobacterium infantis DSM24737, Lactobacillus acidophilus DSM24735, Lactobacillus plantarum DSM24730,
Lactobacillus paracasei DSM24733, Lactobacillus delbrueckii ssp. bulgaricus DSM24734;). HIV+ patients
also underwent fecal sampling after two months of probiotic supplementation (T2) to evaluate the
adherence to probiotics intake and the intervention safety. The control group underwent fecal sampling
at T0.
During the study period, participants were told not to change their usual dietary habits with
particular regard to phenylalanine and tyrosine rich foods.
4.4. Peripheral Immune Activation
PBMC were collected and aliquoted in 1 × 106 cells/mL RPMI medium plus 10% Fetal Bovine
Serum and then washed by centrifugation. The following anti-human monoclonal antibodies were
added: CD3-PerCP, CD4+-APC-Vio770, CD8+-FITC, CD4+ 5RO-PEVio770, CD27-VioBlue, CD38-APC,
(Miltenyi Biotec, Bergisch Gladbach, Germany). Samples were acquired by Miltenyi Biotec flow
cytometer-MACSQuant Analyzer (8 fluorescence channels, 3 lasers). Gating and data analysis were
performed using MACSQuantify software 2.5 (Miltenyi Biotec, Bergisch Gladbach, Germany).
4.5. Fecal Metabolome
For Nuclear Magnetic Resonance (NMR) analysis, 80 mg of frozen stool samples were mixed with
1 mL of deionized water by vortex mixing them for 5 min, followed by centrifugation for 15 min at
18,000 g and 4 ◦C. 100 µL of a D2O solution of 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid sodium salt,
10 mM, set at pH 7.00 with 1-M phosphate buffer were added to about 700 mL of supernatant. Before
analysis, the samples were again centrifuged. Proton NMR (1H-NMR) spectra were recorded at 298
K with an AVANCE III spectrometer (Bruker, Milan, Italy) operating at a frequency of 600.13 MHz.
The Hydrogen Deuterium Oxide residual signal was suppressed by presaturation, whereas broad
signals from slowly tumbling molecules were removed by including a Carr–Purcell–Meiboom–Gill
filter [38] to a free induction decay sequence. The filter was made up by a train of 400 echoes separated
by 800 µs, for a total time of 328 ms. Each spectrum was acquired by summing up 256 transients using
32 K data points over a 7211.54-Hz spectra (for an acquisition time of 2.27 s). The recycle delay was set
to 8 s, considering the longitudinal relaxation time of the protons under investigation. A representative
1H-NMR spectrum for phenylalanine and tyrosine quantification was reported in Figure 5. Spectra
were adjusted for phase and baseline in Topspin ver. 3.5 (Bruker, Milan, Italy). Any other further
processing was performed in R computational language (www.r-project.org) as detailed by Foschi et
al. [39]. In detail, molecules’ quantification was performed in the first sample acquired by employing
the added Trimethylsilylpropanoic acid (TSP) as an internal standard. In order to compensate for
differences in solids content, any other sample was then normalized to such sample by means of
normalized absolute quantification [40]. Integration of the signals was performed for each molecule by
means of rectangular integration.
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4.6. Bacterial DNA Isolation from Fecal Samples
Bacterial DNA was evaluated on fecal samples in order to assess patients’ adherence to probiotics
intake and to evaluate the efficacy f the product to modify intestinal microbiota composition.
For this purpos , QIAamp DNA Stool Mini Kit (Qiagen, Hil en, Ger any) was used according to
the manufacturer’s instructions: 200 mg of frozen samples were suspended in 1.4 mL of ASL lysis
buffer from stool kit, added with glass beads (150–212) µ , (Sigma-Aldrich, St. Louis, MO,
USA), and homogenized. The suspension was incubate at 95 ◦C for 5 min, DNA was purified and
eluted in 200 µL of AE buff r and the amples obtained wer stored at −20 ◦C. Finally, bacterial DNA
from faecal samples was quantified by a re l-time PCR, performed to ev luate Bifidobacteri levels.
Briefly, PCR amplification and detection were p rfor d on o tical-grade 96-well plates, using the
Applied Biosystems 7500 Re l-Time PCR ins rument (A plied Biosystems, Inc., Norwalk, CT, USA).
The reaction mixture was composed of SensiMix SYBR Low-ROX (BIOLINE, Taunto , MA, USA),
500 nM prim rs for Bifidobact rium genus, and 2.5 µL of template DNA (final volume = 25 µL).
After amplification, a melting curve an lysis was made to istinguish arget amplicons from aspecific
non-targe PCR roducts. Standard curves were made by using 10-fold dilutions of DNA, extracted
from Bifid bacterium breve. All amples were analys d in duplicate in two in epende t real-time
PCR assays.
4.7. ELISA Assay for Evaluation of CSF Neopterin Levels
CSF was collected by lumbar puncture and cell-free centrifuged supernatant samples were stored
at−80 ◦C. CSF neopterin levels were determin d by a ommercially available solid phase enzyme-linked
immunosorbent assay (ELISA), based on the basic principle of petitive ELISA (IBL International
GmbH, Hamburg, Germany), as previously described [19].
4.8. Neurocognitive Evaluation
A trained neuropsychologist carried out several neuropsychological tests to all HIV+ patients in
order to explore ability in the following areas: verbal, language, attention, learning memory, working
memory, abstraction, executive functions, processing speed of information, sensory-perceptual and
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motor. The test battery included: Rey-Osterrieth Complex Figure Test (ROCF) to evaluate participants’
recognition and recall skills for non-verbal contents, Rey Auditory Verbal Learning Test (RAVLT) to
evaluate short term auditory-verbal memory, rate of learning and retention of information, Test of
Weights and Measures Estimation (STEP) to evaluate abstraction skills, Visual Search Test (Attention
Matrices Test) to evaluate attention skills, Verbal Fluency test (FAB) to evaluate executive functions
and the ability to switch between different tasks, Test of Phonological and Semantic Verbal Fluency
(respectively PVF and SVF) to evaluate phonological and semantic supplies and the ability to access
them, Raven’s Standard Progressive Matrices (SPM) to evaluate abstract reasoning and problem solving
capabilities, Digit Span test to evaluate short term memory and executive functions, Corsi Block
Tapping Test (CBTT) to evaluate short term spatial memory and executive functions, Aachener Aphasia
Test (AAT) to evaluate the presence of aphasia among study participants, Trail Making Test A and B
(TMT A and TMT B) to evaluate visual-spatial attention and motor skills.
4.9. Statistical Analysis
Data are presented as Mean and standard deviation (SD) or median and range
(minimum-maximum). Paired sample t-test or Wilcoxon signed-rank test were applied to evaluate
paired samples between T0 and T6. A Kolmogorov–Smirnov test was applied to verify the normal
distribution of values of the considered variables and, based on the evidence obtained, independent
sample t-test was subsequently applied to analyse variables that showed a normal distribution,
while the Wilcoxon signed-rank test test was applied in the case that the variables did not show a
normal distribution. A multivariate analysis was the conducted to evaluate the impact of probiotic
intake on the observed modifications of amino acids concentration to assess significance, an F test that
accounted for design effects has been used.
5. Conclusions
The results from our study are consistent with previously reported data that showed a beneficial
effect of probiotics on systemic immune activation, CNS inflammation and neurocognitive function.
Despite the small sample size and the lack of the neurotransmitters concentration measurement,
our study highlights the beneficial effect of this compound on cognitive performance in virologically
suppressed HIV-1 infected individuals; we speculated that this could be at least partially explained by
the modulation of tetrahydrobiopterin activity and the restoration of the dopamine synthesis pathway.
Accordingly, probiotic supplementation deeply impacts on the metabolism of the essential amino acid
Phe, which is severely altered during HIV-1 infection [9], improving its conversion to Tyr. Nevertheless,
our data further support previous evidence about the advantageous effect of adjunctive therapies on T
cell immune activation and gut epithelial integrity recovery in HIV-1 infected patients [41,42]. Further
investigations are needed to confirm our preliminary data and to investigate probiotics role in the
setting of symptomatic neurocognitive impairment in order to introduce this therapeutic strategy to
everyday clinical practice and improve the complex management of this population.
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